Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?

Adma Biologics (ADMA) shares soared 10.2% in the last trading session to close at $20.61. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.7% gain over the past four weeks.The sudden soaring of the stock price can be attributed to a positive investor mindset regarding the continued sales growth of ADMA Biologics’ three FDA-approved products, namely – Bivigam (to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus). In 2024, the company recorded total revenues of $426.5 million entirely from product sales, representing an increase of 65% on a year-over-year basis.This infectious disease drug developer is expected to post quarterly earnings of $0.16 per share in its upcoming report, which represents a year-over-year change of +100%. Revenues are expected to be $119.1 million, up 45.5% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Adma Biologics, the consensus EPS estimate for the quarter has been revised 6.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ADMA going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Adma Biologics is part of the Zacks Medical - Biomedical and Genetics industry. Wave Life Sciences (WVE), another stock in the same industry, closed the last trading session 2.6% higher at $10.04. WVE has returned -11.2% in the past month.For Wave Life Sciences, the consensus EPS estimate for the upcoming report has changed +2% over the past month to -$0.26. This represents a change of -8.3% from what the company reported a year ago. Wave Life Sciences currently has a Zacks Rank of #3 (Hold).Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis Report WAVE Life Sciences Ltd. (WVE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks